- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | FDA grants ODD to Ractigen Therapeutics' RAG-21 for ALS treatment | ||
| Di | Arrowhead Pharmaceuticals submits plozasiran NDA to treat FCS | ||
| Mo | Numab Therapeutics and Kaken Pharmaceutical collaborate to develop ND081 | ||
| Fr | FDA to review Sanofi, Regeneron's Dupixent sBLA for CSU | ||
| 14.11. | Asha Therapeutics secures grant for ALS therapeutic development | ||
| 13.11. | AstraZeneca and Daiichi Sankyo submit BLA to FDA for lung cancer treatment | ||
| 12.11. | Lakeside Holding agrees to acquires Hupan Pharmaceutical | ||
| 11.11. | Alteogen and Daiichi Sankyo sign license deal for ADC development | ||
| 08.11. | New England Biolabs opens new manufacturing facility in UK | ||
| 07.11. | Plus Therapeutics partners with SpectronRx for CNS therapy development | ||
| 06.11. | Insignis Therapeutics' IN-001 clinical programme receives positive FDA response | ||
| 05.11. | Ring Therapeutics signs partnerships to advance R&D in biomedical sciences | ||
| 04.11. | NEOGAP and NorthX Biologics partner for cancer cell therapy production | ||
| 01.11. | Electra Therapeutics secures FDA ODD status for HLH treatment | ||
| 31.10. | Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14 | ||
| 30.10. | FDA expands approval for Shorla's JYLAMVO to paediatric patients | ||
| 29.10. | Kivu Bioscience secures $92m in Series A funding for ADC development | ||
| 28.10. | FDA grants IND clearance for RiboX's RXRG001 | ||
| 25.10. | Lyell signs agreement to acquire ImmPACT Bio | ||
| 24.10. | FDA issues CRL to PharmaTher's ketamine ANDA | ||
| 23.10. | TerSera acquires global rights to MacroGenics' MARGENZA for breast cancer treatment | ||
| 22.10. | Samsung Biologics signs $1.24bn manufacturing deal with Asian pharma company | ||
| 21.10. | Novartis gets positive CHMP opinion for Kisqali in early breast cancer | ||
| 18.10. | AscellaHealth acquires specialty pharmaceutical wholesaler CHAPPER healthcare | ||
| 17.10. | Astria Therapeutics' navenibart gains orphan medicinal status from EC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
